References
- Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. 2001. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 92(7):1759–1768.
- Camacho-Barquero L, Villegas I, Sánchez-Calvo JM, Talero E, Sánchez-Fidalgo S, Motilva V, et al. 2007. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol. 7(3):333–342.
- Degen A, Alter M, Schenck F, Satzger I, Völker B, Kapp A, et al. 2010. The hand-foot-syndrome associated with medical tumor therapy—classification and management. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 8(9):652–661.
- Franceschini J, Jardim JR, Fernandes ALG, Jamnik S, Santoro IL. 2010. Reproducibility of the Brazilian Portuguese version of the European organization for research and treatment of cancer core quality of life questionnaire used in conjunction with its lung cancer-specific module. J Bras Pneumol. 36(5):595–602.
- Janusch M, Fischer M, Marsch WC, Holzhausen H-J, Kegel T, Helmbold P. 2006. The hand-foot syndrome—a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol EJD. 16(5):494–499.
- Jurenka JS. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev J Clin Ther. 14(2):141–153.
- Kang Y-K, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. 2010. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol Off J Am Soc Clin Oncol. 28(24):3824–3829.
- McMillan DC. 2013. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 39(5):534–540.
- Milano G, Etienne-Grimaldi M-C, Mari M, Lassalle S, Formento J-L, Francoual M, et al. 2008. Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol. 66(1):88–95.
- Paula HR de, Haddad A, Weiss MA, Dini GM, Ferreira LM, Paula HR de, et al. 2014. Translation, cultural adaptation, and validation of the American Skindex-29 quality of life index. An Bras Dermatol. 89(4):600–607.
- Protocol Development | CTEP [Internet]. [cited 2017 Mar 26 ]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm.
- Saif MW. 2011. Capecitabine and hand-foot syndrome. Expert Opin Drug Saf. 10(2):159–169.
- Wolf SL, Qin R, Menon SP, Rowland KM, Thomas S, Delaune R, et al. 2010. Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol. 28(35):5182–5187.
- Yap YS, Kwok L-L, Ng RCH, Wong NS, Lo SK, Chay WY, et al. 2015 [cited 2017 Mar 22]. Predictors of hand-foot syndrome (HFS) in randomised double-blind, placebo-controlled trial of pyridoxine for prevention of capecitabine induced HFS. J Clin Oncol [Internet]. 33(suppl; abstr 9596). Available from: http://meetinglibrary.asco.org/content/144116-156.
- Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. 2012. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol Off J Eur Soc Med Oncol. 23(5):1348–1353.